The United Laboratories International Holdings (HK:3933) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The United Laboratories International Holdings Limited has announced the successful completion of Phase Ia clinical trials for their new drug, UBT251 Injection, in China. The drug, a first-in-class long-acting triple agonist, demonstrated safety, tolerability, and linear pharmacokinetics when administered to healthy subjects. Furthermore, it showed promising results in reducing body weight compared to a placebo, positioning the company as a pioneer in the Chinese biopharmaceutical industry.
For further insights into HK:3933 stock, check out TipRanks’ Stock Analysis page.